The funding of research into the cause and possible treatment of epidermolysis bullosa is one of DebRA UK’s main activities.
DebRA UK is the largest provider of EB research funds of all of the national DebRAs around the world and also manages a centralised research grant assessment process on behalf of all of the member groups of DebRA International. This enables funding to be concentrated and coordinated, avoiding unnecessary duplication. A great deal of progress has been made over recent years in understanding the condition.
DebRA’s current research priorities are to:
- Work towards the development of gene therapy
- Understand the nature of cancer in recessive dystrophic EB
- Understand the nature of wound healing in EB
- Improve the management of EB through clinical research
In this section you will find details of DebRa International, DebRA's policy towards the use of animals in scientific research, details about our Medical and Scientific Advisory Panel and outlines of our current research projects.
